The Phase II clinical trial involves the leading drug in Can-Fite's pipeline.
Can-Fite BioPharma Ltd. (TASE:CFBI) has completed recruitment for the Phase II clinical trial of its CF-101 drug for the treatment of dry-eye syndrome (keratoconjunctivitis sicca). 80 patients will participate in the trial at six Israeli medical centers. Patients will take the drug over twelve weeks and monitored for two more weeks.
Can-Fite expects to publish the results of the trial during the second quarter of 2009.
Dry-eye syndrome is a chronic illness that affects tear production. It causes irritation and inconvenience, and can lead to temporary or permanent eye damage. It is often associated with rheumatoid arthritis. More than six million people suffer from dry-eye syndrome in the US alone.
CF-101 is Can-Fite's leading drug candidate. In addition to the trial for dry-eye syndrome, the drug is undergoing a Phase IIa clinical trial for the treatment of psoriasis, and a Phase IIb trial for the treatment of rheumatoid arthritis. The company recently completed patient recruitment for the latter trial.
Published by Globes [online], Israel business news - www.globes-online.com - on January 28, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009